JUPITER NEUROSCIENCES, INC. JUNS
other sections of this Annual Report on Form 10-K, includes statistical and other industry and market data that we obtained from industry
publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and
studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee
the accuracy or completeness of such information. While we believe that these industry publications and third-party research, surveys
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $21.8K | $0 | — | — |
| Cost of revenue | $4.2K | — | — | — |
| Gross profit | $17.6K | — | — | — |
| R&D | $2.1M | $492.7K | $954.8K | — |
| SG&A | $6.8M | $2.6M | $2.9M | — |
| Total operating expenses | $8.9M | $3.1M | $3.9M | — |
| Operating income | -$8.9M | -$3.1M | -$3.9M | — |
| Interest expense | $66.0K | $248.4K | $218.7K | — |
| Net income | -$8.6M | -$2.4M | -$4.8M | — |
| EPS, basic | -0.25 | -0.08 | -0.18 | — |
| EPS, diluted | -0.25 | -0.08 | -0.18 | — |
| Shares, diluted (wtd. avg.) | 34.6M | 28.8M | 26.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Receivables | $2.6K | — | — | — |
| Inventory | $159.8K | — | — | — |
| Total current assets | $4.8M | $4.7M | $28.7K | — |
| Total assets | $5.6M | $6.2M | $148.6K | — |
| Accounts payable | $638.6K | $396.5K | $546.0K | — |
| Total current liabilities | $7.4M | $2.0M | $5.8M | — |
| Total liabilities | $7.4M | $2.0M | $5.9M | — |
| Retained earnings | -$34.7M | -$26.0M | -$23.6M | — |
| Total equity | -$1.8M | $4.2M | -$5.8M | -$7.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$5.4M | -$3.9M | -$481.0K | — |
| Stock-based compensation | $2.4M | $1.8M | $50.0K | — |
| Financing cash flow | $5.4M | $7.7M | $445.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014687.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | $0 | $21.8K |
| Gross profit | — | — | — | $17.6K |
| Net income | — | -$4.8M | -$2.4M | -$8.6M |
Recent filings and events
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Other event Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed Item 5.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |